Paramita Therapeutics, Inc. (Paramita) began operations in 2018 and is an early-stage biotech startup focused on development of water-soluble multivalent conjugation platform technologies. Our mission is to eradicate cancer and infectious disease. After the pre-seed fund was obtained in late 2018, we have developed our new water-soluble multivalent platform and generated proof-of-concept data in mice. Now, Paramita is seed-funded by National Science Foundation (NSF) through a Phase 1 SBIR Award to develop multivalent peptide conjugates for a dual-function therapeutic and vaccine product of COVID-19. We are actively seeking for funds to continue with our research and development of our cancer drugs and dual-function therapeutic/vaccine product. Our Founders include Drs. Sang Van, Jack Bui, and Sue Zhong,
Paramita is the first and only biotech company with patented small molecule water-soluble multivalent drug conjugates for treating cancer and infectious disease.
Company Details
- Employees
- 4
- Founded
- -
- Address
- San Diego, California, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- IT Consulting.
- HQ
- San Diego, California
Paramita Therapeutics, Inc. Questions
Paramita Therapeutics, Inc.'s website is http://www.paramita-therapeutics.com
Paramita Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/paramita-therapeutics-inc
Paramita Therapeutics, Inc. has
4 employees.
View email and phone details for 4
employees at Paramita Therapeutics, Inc..
Paramita Therapeutics, Inc.'s industry is
Biotechnology Research
Paramita Therapeutics, Inc.'s top competitors are
Astraea Therapeutics,
Peace Systems Corporation,
Bluelight Therapeutics, Inc.,
Oryn Therapeutics,
Gemini Biosciences,
Smartpharm,
Zata Pharmaceuticals, Inc.,
Teon Therapeutics Inc.,
Green Wise Home Inc.,
Halo Biologics.
Paramita Therapeutics, Inc.'s categories are Biotechnology Research
Paramita Therapeutics, Inc.'s founding year is 2018
